CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,593,980 | -19.1% | 233,399 | +0.1% | 0.01% | -16.7% |
| Q2 2023 | $13,091,735 | +24.1% | 233,198 | +0.0% | 0.01% | +20.0% |
| Q1 2023 | $10,545,963 | -11.8% | 233,163 | -20.7% | 0.01% | -16.7% |
| Q4 2022 | $11,953,986 | -38.2% | 294,071 | -0.6% | 0.01% | -45.5% |
| Q3 2022 | $19,341,000 | +8.8% | 295,972 | +1.1% | 0.01% | +22.2% |
| Q2 2022 | $17,784,000 | -3.3% | 292,646 | -0.1% | 0.01% | +28.6% |
| Q1 2022 | $18,389,000 | -22.3% | 292,959 | -6.3% | 0.01% | -22.2% |
| Q4 2021 | $23,681,000 | -33.7% | 312,503 | -2.1% | 0.01% | -30.8% |
| Q3 2021 | $35,730,000 | -30.3% | 319,215 | +0.8% | 0.01% | -35.0% |
| Q2 2021 | $51,268,000 | -49.3% | 316,690 | -61.8% | 0.02% | -51.2% |
| Q1 2021 | $101,056,000 | -20.0% | 829,354 | +0.5% | 0.04% | -22.6% |
| Q4 2020 | $126,325,000 | +67.5% | 825,062 | -8.5% | 0.05% | +43.2% |
| Q3 2020 | $75,427,000 | -9.8% | 901,813 | +0.3% | 0.04% | -14.0% |
| Q2 2020 | $83,629,000 | +345.2% | 899,521 | +103.1% | 0.04% | +230.8% |
| Q1 2020 | $18,785,000 | -29.2% | 442,947 | +1.7% | 0.01% | -7.1% |
| Q4 2019 | $26,533,000 | +52.4% | 435,644 | +2.6% | 0.01% | +55.6% |
| Q3 2019 | $17,405,000 | -13.0% | 424,613 | 0.0% | 0.01% | -18.2% |
| Q2 2019 | $20,000,000 | +31.9% | 424,613 | 0.0% | 0.01% | +37.5% |
| Q1 2019 | $15,167,000 | +10.7% | 424,613 | -11.4% | 0.01% | 0.0% |
| Q4 2018 | $13,696,000 | -35.6% | 479,363 | 0.0% | 0.01% | -27.3% |
| Q3 2018 | $21,259,000 | -49.9% | 479,363 | -33.6% | 0.01% | -50.0% |
| Q2 2018 | $42,412,000 | +30.4% | 721,783 | +1.4% | 0.02% | +37.5% |
| Q1 2018 | $32,534,000 | +74.4% | 711,733 | -10.4% | 0.02% | +77.8% |
| Q4 2017 | $18,656,000 | +43.1% | 794,533 | +8.9% | 0.01% | +50.0% |
| Q3 2017 | $13,033,000 | +11.5% | 729,333 | 0.0% | 0.01% | 0.0% |
| Q2 2017 | $11,684,000 | -25.8% | 729,333 | 0.0% | 0.01% | -25.0% |
| Q1 2017 | $15,738,000 | +9.4% | 729,333 | 0.0% | 0.01% | +14.3% |
| Q4 2016 | $14,389,000 | – | 729,333 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |